Recursion Pharmaceuticals (RXRX) Goodwill & Intangibles (2020 - 2026)

Recursion Pharmaceuticals has reported Goodwill & Intangibles for 7 years, with the latest figure at $454.2 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles fell 8.03% year-over-year to $454.2 million; the trailing twelve-month figure through Mar 2026 stood at $454.2 million (down 8.03% YoY), and the FY2025 full-year result was $472.1 million, down 2.61% from the prior year.
• Goodwill & Intangibles for Q1 2026 stood at $454.2 million, down from $472.1 million in the prior quarter.
• The five-year high for Goodwill & Intangibles was $505.6 million in Q2 2025, with the low at $2.0 million in Q2 2022.
• Historically, Goodwill & Intangibles has averaged $203.0 million across 5 years, with a median of $90.3 million in 2024.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles retreated 13.0% — and 2023, when it jumped 4977.34%.
• Recursion Pharmaceuticals' Goodwill & Intangibles stood at $2.1 million in 2022, then soared by 4100.24% to $88.5 million in 2023, then surged by 447.72% to $484.7 million in 2024, then retreated by 2.61% to $472.1 million in 2025, then decreased by 3.77% to $454.2 million in 2026.
• The last three Goodwill & Intangibles figures came in at $454.2 million (Q1 2026), $472.1 million (Q4 2025), and $484.4 million (Q3 2025), per Business Quant data.